TrialOrphanet journal of rare diseases2017

Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.

Ania C Muntau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.